Ralph Carmona, a 74-year-old Portland man who has Alzheimer's, says he is a living example of the value of medical research.

Carmona said, gesturing toward a wall filled with race bibs and ribbons. Sign up for our Newsletters Carmona, a Portland resident, will be running this year’s Boston Marathon. But as he makes his way ...

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

Alzheon's Alzheimer's drug showed nominal benefit in a subgroup of patients who suffer with mild cognitive impairment.

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...